Chemoenzymatic Synthesis of Heparin Oligosaccharides with both Anti-factor Xa and Anti-factor IIa Activities

被引:38
|
作者
Xu, Yongmei [1 ]
Pempe, Elizabeth H. [1 ]
Liu, Jian [1 ]
机构
[1] Univ N Carolina, Eshelman Sch Pharm, Div Chem Biol & Med Chem, Chapel Hill, NC 27599 USA
基金
美国国家卫生研究院;
关键词
INDUCED THROMBOCYTOPENIA; ANTITHROMBIN-III; TERNARY COMPLEX; SULFATE; ANTICOAGULANT; BINDING; BIOSYNTHESIS; REPLACEMENT; SPECIFICITY; REVEALS;
D O I
10.1074/jbc.M112.358523
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Heparan sulfate (HS) and heparin are highly sulfated polysaccharides. Heparin is a commonly used anticoagulant drug that inhibits the activities of factors Xa and IIa (also known as thrombin) to prevent blood clot formation. Here, we report the synthesis of a series of size-defined oligosaccharides to probe the minimum size requirement for an oligosaccharide with anti-IIa activity. The synthesis was completed by a chemoenzymatic approach involving glycosyltransferases, HS sulfotransferases, and C-5-epimerase. We demonstrate the ability to synthesize highly purified N-sulfo-oligosaccharides having up to 21 saccharide residues. The results from anti-Xa and anti-IIa activity measurements revealed that an oligosaccharide longer than 19 saccharide residues is necessary to display anti-IIa activity. The oligosaccharides also exhibit low binding toward platelet factor 4, raising the possibility of preparing a synthetic heparin with a reduced effect of heparin-induced thrombocytopenia. The results from this study demonstrate the ability to synthesize large HS oligosaccharides and provide a unique tool to probe the structure and function relationships of HS that require the use of large HS fragments.
引用
收藏
页码:29054 / 29061
页数:8
相关论文
共 50 条
  • [21] Lack of Inter-Laboratory Agreement in the Monitoring of Unfractionated Heparin Using the Anti-Factor Xa Activity and the Anti-Factor Xa-Correlated Activated Partial Thromboplastin Time
    Toulon, Pierre
    Smahi, Motalib
    De Pooter, Neila
    Zereg, Elamine
    [J]. BLOOD, 2017, 130
  • [22] ANTI-FACTOR XA ACTIVITY MEASURED WITH AMIDOLYTIC METHODS
    ODEGARD, OR
    LIE, M
    ABILDGAARD, U
    [J]. HAEMOSTASIS, 1976, 5 (05) : 265 - 275
  • [23] ANTI-FACTOR XA ACTIVITY OF HEPARAN-SULFATE
    THOMAS, DP
    MERTON, RE
    BARROWCLIFFE, TW
    MULLOY, B
    JOHNSON, EA
    [J]. THROMBOSIS RESEARCH, 1979, 14 (2-3) : 501 - 506
  • [24] ANTI-FACTOR XA DETERMINATION IN BLOOD - A NEW METHOD FOR CONTROLLING HEPARIN-THERAPY
    HARENBERG, J
    HAAF, B
    SCHAFER, M
    DEMPFLE, CE
    STEHLE, G
    HEENE, DL
    [J]. SEMINARS IN THROMBOSIS AND HEMOSTASIS, 1993, 19 : 79 - 85
  • [25] ANTI-FACTOR XA MONITORING OF HEPARIN FOR THE TREATMENT OF PULMONARY EMBOLISM MANAGED BY A PERT TEAM
    Zhu, Eric
    Yuriditsky, Eugene
    Raco, Veronica
    Katz, Alyson
    Papadopoulos, John
    Pashun, Raymond
    Horowitz, James
    Ahuja, Tania
    [J]. CRITICAL CARE MEDICINE, 2024, 52
  • [26] Comparing Anti-Factor Xa and Activated Partial Thromboplastin Levels for Monitoring Unfractionated Heparin
    Wahking, Rebekah A.
    Hargreaves, Rachel H.
    Lockwood, Sean M.
    Haskell, Sabrina K.
    Davis, Kelly W.
    [J]. ANNALS OF PHARMACOTHERAPY, 2019, 53 (08) : 801 - 805
  • [27] Study of two techniques for heparin therapy monitoring with an amidolytic anti-factor Xa assay
    Rosborough, TK
    Wolfson, PA
    [J]. LABORATORY MEDICINE, 2002, 33 (10) : 789 - 790
  • [28] ANTI-FACTOR XA VERSUS ACTIVATED PARTIAL THROMBOPLASTIN TIME FOR HEPARIN INFUSION MONITORING
    Jung, Sul
    Choi, Austin
    Lepore, Mark
    [J]. CRITICAL CARE MEDICINE, 2020, 48
  • [29] A Systemwide Approach for Navigating the Dilemma of Oral Factor Xa Inhibitor Interference With Unfractionated Heparin Anti-Factor Xa Concentrations
    Levito, Marissa N.
    Coons, James C.
    Verrico, Margaret M.
    Szymkowiak, Adrienne
    Legler, Brianna
    Dueweke, Eric J.
    Kane-Gill, Sandra L.
    [J]. ANNALS OF PHARMACOTHERAPY, 2021, 55 (05) : 618 - 623
  • [30] Low Molecular Weight Heparin Anti-Factor Xa Level Monitoring in a Healthcare System
    Quesep, Natalie
    Menendez, Lourdes
    Dittmar, Erika
    Gopalani, Radhan
    Patel, Payal
    Clarke, Heidi
    Nagalla, Srikanth
    [J]. BLOOD, 2022, 140 : 11374 - 11374